It may be possible to restore drug-resistant neuroendocrine prostate cancer to a state that responds to treatment by depletion of a certain protein in cancer cells. A recent study published in Communications Biology by the University of Eastern Finland found that this protein, DPYSL5, is expressed in neuroendocrine prostate cancer.
Exciting news for men whose cancer has morphed into neuroendocrine..
medicalxpress.com/news/2024...
Not ready yet - but very encouraging. Now if it doesn't take 15 years to get it to market..
New drug could revolutionise prostate cancer treatment 
fenbendazole treatment for Prostate cancer
Newly Identified Prostate Cancer Subtypes May Respond Differently to Treatment
Neuroendocrine prostate cancer
New prostate cancer treatment concept
